Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026
Cytokinetics will announce topline results from the ACACIA-HCM pivotal Phase 3 trial of aficamten in non-obstructive HCM on May 5, 2026. A conference call and webcast is scheduled for 8:00 AM Eastern Time to discuss the data.
Key figures
- Drug Name
- aficamten (MYQORZO)
- Phase Of Trial
- Phase 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.